2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
20
Active not recruiting
11
Terminated
3
Not yet recruiting
2
Withdrawn
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Interventions
Cyclophosphamide
1495
Cisplatin
1431
Paclitaxel
1339
Radiotherapy
1308
Carboplatin
1264
Gemcitabine
1225
Docetaxel
1134
Bevacizumab
1068
Fluorouracil
906
Doxorubicin
799
Dexamethasone
753
Rituximab
744
Capecitabine
735
Oxaliplatin
709
pembrolizumab
693
Etoposide
674
Irinotecan
639
Filgrastim
624
Nivolumab
585
Cytarabine
585
Leucovorin
582
Vincristine
512
Cetuximab
478
Prednisone
477
Bortezomib
472
Trastuzumab
469
Erlotinib Hydrochloride
467
Surveys and Questionnaires
460
Methotrexate
443
Lenalidomide
434
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
iberdomide
×
Clear all
NCT03310619
2024-04-04
PLATFORM
Celgene
Phase 1/2
Completed
62 enrolled
41 charts